Stockreport

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically valid [Read more]